Abstract Because DNA methyltransferase (DNMT) inhibitors like azacytidine and decitabine are known to be effective in the clinic for diseases like myelodysplastic syndromes that may result in part from transcriptional dysregulation due to epigenetic changes, there is interest in developing novel DNMT inhibitors that would be more effective and less toxic. The effects of one such agent, zebularine, which inhibits DNMT and cytidine deaminase, were assessed in two human breast cancer cell lines, MDA-MB-231 and MCF-7. Zebularine treatment inhibited cell growth in a dose and time dependent manner with an IC-50 of *100 lM and 150 lM in MDA-MB-231 and MCF-7 cells, respectively, on 96 h exposure. This was associated with increased expression of p21, decreased expression of cyclin-D, and induction of S-phase arrest. At high doses zebularine induced changes in apoptotic proteins in a cell line specific manner manifested by alteration in caspase-3, Bax, Bcl2 and PARP cleavage. Like other DNMT inhibitors, zebularine decreased expression of DNMTs posttranscriptionally as well as expression of other epigenetic regulators like methyl CpG binding proteins and global acetyl H3 and H4 protein levels. Its capacity to reexpress epigenetically silenced genes in human breast cancer cells at low doses was confirmed by its ability to induce expression of estrogen and progesterone receptor mRNA in association with changes suggestive of active chromatin at the ER promoter as evidenced by ChIP. Finally, its effect in combination with other DNMT or HDAC inhibitors like decitabine or vorinostat was explored. The combination of 50 lM zebularine with decitabine or vorinostat significantly inhibited cell proliferation and colony formation in MDA-MB-231 cells compared with either drug alone. These findings suggest that zebularine is an effective DNMT inhibitor and demethylating agent in human breast cancer cell lines and potentiates the effects of other epigenetic therapeutics like decitabine and vorinostat.
Introduction
Breast cancer results from an accumulation of genetic and epigenetic events. Multiple mutations have been identified in primary breast cancers [1] but such changes are difficult to overcome. In contrast, most epigenetic modifications are post-transcriptional, reversible events that do not target gene sequence [2, 3] , and inhibition of these mechanisms could theoretically be advantageous in the treatment of breast cancer. As a consequence the role of epigenetic regulators like histone deacetylase (HDAC) and DNA methyltransferase (DNMT) inhibitors as treatment for breast cancer is under evaluation.
The two well characterized and clinically relevant DNMT inhibitors, azacytidine (aza) and decitabine (5-azaDc) are nucleoside analogue mechanism-based inhibitors. They M. Billamsubstitute for cytosine residues in DNA during replication and inhibit DNMT activity through covalent binding to the DNMT enzymes, resulting in reduced genomic DNA methylation [4] [5] [6] [7] . Although effective against certain hematopoietic disorders, these drugs have some toxicity both in vitro and in vivo and are unstable in neutral solutions [8, 9] . Further, deamination of these analogues by cytidine deaminases results in their inactivation. Hence a nontoxic, highly stable, effective DNMT inhibitor would be an ideal epigenetic therapeutic.
One such putative agent is zebularine, a cytidine analog containing a 2-(1H)-pyrimidinone ring that was originally developed as a cytidine deaminase inhibitor [10] [11] [12] to prevent deamination of nucleoside analogues. Zebularine is also a versatile starting material for the synthesis of complex nucleosides and is a mechanism based DNA cytosine methyltransferase inhibitor [13] . It acts primarily as a trap for DNMT protein by forming tight covalent complexes between DNMT protein and zebularine-substituted DNA [14] . In contrast to other DNMT inhibitors, it has low toxicity in most cell lines tested [15] [16] [17] and is quite stable with a half-life of 510 h at pH 7.4 [13] . Because of its low toxicity, continuous administration of effective doses of zebularine alone or in combination with other DNMT inhibitors is feasible and this can result in the enhanced reexpression of epigenetically silenced genes in cancer cells [18] .
Several preclinical studies have evaluated zebularine as a possible therapeutic in cancer cell lines. Zebularine preferentially incorporates into DNA, leading to cell growth inhibition and increased expression of cell cycle regulatory genes in cancer cell lines compared with normal fibroblasts [19] . It was also found to reactivate expression of several abnormally silenced methylated genes like p16 in T24, HCT15, CFPAC-1, SW48 and HT-29 cells [19] ; E-cadherin in Akata cells [17] ; and p15INK4B in AML 193 cells [16] . However, its effects on breast cancer cells have not been reported. Here, the demethylating and cytotoxic effects of zebularine in human breast cancer cell lines were evaluated and the utility of zebularine in conjunction with other epigenetic modifiers was explored.
Materials and methods

Reagents
Zebularine was a kind gift from Dr. Victor Marquez (National Cancer Institute). DNMT1 antibody was provided by Dr. William Nelson, Johns Hopkins University [20] . Antibodies to Bcl2; Bax; caspases 3, 8 and 9; cyclins B and D; p21; and p27 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against acetylated H3 and H4 and poly(ADP-ribose) polymerase (PARP) were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY) while DNMT3a and DNMT3b antibodies were from Affinity BioReagents (Golden, CO) and Novus Biologicals (Littleton, CO), respectively.
Cell lines and culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 were maintained at 37°C, 5% CO 2 in DMEM supplemented with 5% fetal bovine serum (Hyclone, Logan, UT) and 2 lmol/l L-alanyl-L-glutamine (Mediatech, Herndon, VA). For treatment, cells were seeded at a density of 3 9 10 5 per 100-mm tissue culture dish in phenol red-free DMEM supplemented with 5% charcoal-treated FBS (estrogen stripped medium) (Hyclone, Logan, UT). After 24 h, the estrogen stripped medium was changed to estrogen stripped medium containing zebularine for 96 h.
Cell proliferation assays 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro mide (MTT) assay was performed as previously described to evaluate the effects of different concentrations of zebularine for 24, 48, 72, or 96 h [21] . The results of MTT assays were validated by comparison with conventional cell counting using coulter counter. For combination study cells were treated with 50 lM zebularine, 1 lM 5-azaDc and 2.5 lM vorinostat (suberoylanilide hydroxamic acid or SAHA).
Flow cytometry
For flow cytometry MDA-MB-231 and MCF-7 cells plated at a cell density of 100,000 cells in 10-cm culture dishes were treated with different doses of zebularine for 96 h. Cells were collected by trypsinization, washed with icecold phosphate-buffered saline, fixed with 4.44% formaldehyde (Sigma), and stained with Hoechst 33258 (Sigma). BD-LSR (BD Biosciences) was used to perform FACS, and the cell cycle was analyzed using Cell-Quest software (BD Biosciences).
Colony formation assay
After trypsinization, single cell suspensions of MDA-MB-231 cells (200 cells/well) were plated in 6-well plates. Media was replaced with drug containing media 24 h later and then every 3 days for the entire period of study. After 10 days the colonies were rinsed with PBS, fixed, and stained with crystal violet solution [22] . Assays were performed in triplicate for each independent experiment.
Western blot and histone analysis MDA-MB-231 and MCF-7 cells treated with different doses of zebularine for 96 h were washed with ice-cold PBS, harvested by gentle scraping, and lysed with protein extraction buffer containing 150 mmol/l NaCl, 10 mmol/l Tris (pH 7.2), 5 mmol/l ethylenediaminetetraacetic acid (EDTA), 0.1% Triton X-100, 5% glycerol, and 2% SDS. Samples were electrophoresed on 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes for hybridization with primary antibodies followed by peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:5,000; DAKO Corp., Carpinteria, CA) and enhanced chemiluminescence staining (Amersham Biosciences, Piscataway, NJ). The expression of b-actin was used as control.
Histone proteins from cells treated with zebularine were isolated according to previously published protocols [23] . From control and zebularine-treated cells, about 3-5 lg of histone protein was analyzed by Western blotting using anti-acetyl histone3 (H3) and anti-acetyl histone4 (H4) antibodies (1:1,000; Upstate Biochemical, Lake Placid, NY) and horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:2,000).
Band intensity from scanned images of western blots was calculated by densitometric analysis using Image J software (http://rsb.info.nih.gov/ij/). Analysis was done on at least three replicates for each experiment.
Reverse transcription and PCR RNA was harvested from zebularine-treated MDA-MB-231 and MCF-7 cells by Trizol reagent (Invitrogen, Carlsbad, CA) as previously described [24] . Reverse transcription was done with 3 lg RNA using MMLV reverse transcriptase (Invitrogen) and oligo dT primers at 42C for 1 h. Conventional PCR was performed on cDNA samples with gene specific primers, and the PCR products were resolved on 2% agarose gels and visualized by ethidium bromide staining. The primers used were ER a S: GCA CCC TGA AGT CTC TGG AA and AS: TGG CTA AAG TGG TGC ATG AT; PR S: TCA TTA CCT CAG AAG ATT TGT TTA ATC and AS: TGA TCT ATG CAG GAC TAG ACA A; progesterone receptor (PR) S: TCATT ACCTCAGAAGATTTGTTTAATC and AS: TGATCT ATGCAGGACTAGACAA; actin S: ACC ATG GAT GAT GAT ATC GC and AS: ACA TGG CTG GGG TGT TGA AG.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was done using previously published methods [25] with minor modifications.
Chromatin samples from MDA-MB-231 cells treated with 100 or 200 lM zebularine for 96 h were sonicated on ice thrice for 15 s. The samples were immunoprecipitated with specific antibodies. The immunoprecipitated DNA was ethanol precipitated and resuspended in 30 ll TE buffer. The ER promoter was analyzed using previously published primers [25] . MDA-MB-231 cells treated with 2.5 lM 5-azaDc were used as a positive control.
Data analysis
Data are expressed as mean ± SE for each treatment group. One-way ANOVA was used to compare the differences between control and treatment groups. When significant, ANOVA was, followed by a post-hoc test (Tukeys HSD or Dunnets) as required. Significance was set at a = 0.05. All analyses were performed using GraphPad Prism software (GraphPad Software, Inc. La Jolla, CA).
Results
Zebularine inhibits human breast cancer cell growth in a dose and time dependent manner Human breast cancer cell lines MCF-7 and MDA-MB-231 representing estrogen receptor a (ER)-positive and -negative phenotypes, respectively, were utilized for this study. In addition, numerous studies including our own have documented that expression of multiple genes including ER is epigenetically silenced in MDA-MB-231 cells and the underlying mechanisms have been extensively explored, making this cell line particularly informative for the evaluation of zebularine.
The effect of zebularine (25-500 lM) on cell proliferation after 24, 48, 72 and 96 h of exposure was assessed by MTT assay (Fig. 1) . MDA-MB-231 cells were more sensitive to zebularine treatment with a significant decrease in cell proliferation at most doses tested. The IC50s were [500, 150, 99 and 88 lM, respectively, at 24, 48, 72, and 96 h of exposure (Fig. 1a) . MCF-7 cells were less sensitive to zebularine with IC50 s of [500 lM, 426, 180 and 149 lM at 24, 48, 72 and 96 h, respectively, ( Further, an increase in percentage of cells in S-phase consistent with S-phase arrest was observed at the highest dose of 200 lM in both cell lines. Because of these changes, the effect of zebularine on expression of critical cell cycle proteins was assessed. As previously reported [26, 27] , p21 protein expression was essentially undetectable in MDA-MB-231 cells ( Fig. 2c ) and treatment with zebularine did not alter its expression. However, zebularine decreased p27 protein expression in a dose dependent fashion with a significant decrease at the highest dose (P \ 0.05) (Fig. 2c, d ).
In contrast, zebularine treatment of MCF-7 cells was associated with enhanced p21 expression at 200 lM without significant alteration in P27 expression ( Zebularine induces apoptotic cell death in breast cancer cells
The possibility that zebularine might induce apoptotic cell death was explored by western blot analysis of key apoptosis-associated proteins. In both MDA-MB-231 and MCF-7 cells, treatment with increased doses of zebularine was associated with enhanced cleavage of PARP (116 kDA). PARP cleavage was significant at the two highest doses tested in MCF-7 cells but only at the highest dose in MDA-MB-231 cells (P \ 0.05). Increased expression of caspase 3 without significant alteration of caspase 8 or 9 protein expression was observed in MDA-MB-231 cells (Fig. 3a, b) . In contrast, enhanced expression of caspase 9 and cleavage of PARP were observed in MCF-7 cells that are known to lack caspase 3 expression (Fig. 3a, c) . Expression of antiapoptotic Bcl2 protein was reduced in a dose-dependent manner in both cell lines as was Bax expression in MCF-7 cells. In contrast, Bax expression was significantly upregulated at 50 lM (P \ 0.05), indicating that Bax may be an early response protein, upon zebularine treatment in MDA-MB-231 cells. Together these findings suggest that zebularine treatment of MCF-7 cells induces apoptosis through the intrinsic mitochondrial pathway while zebularine Zebularine inhibits the expression of epigenetic regulators
Because of zebularine's activity as a DNMT inhibitor in other model systems, its effect on expression of DNMTs in breast cancer cells was examined (Fig. 4) . As expected, zebularine treatment was associated with a statistically significant dose-dependent depletion of DNMT1, DNMT3a, and DNMT3b proteins in MCF-7 and MDA-MB-231 cells (Fig. 4a, b) even at the lowest dose tested (50 lM). suggesting that its primary mode of action is posttranscriptional through trapping of DNMT proteins by zebularine incorporated into DNA. Because of the importance of the methyl CpG binding domain proteins (MBDs) in transcriptional repressor complexes, the impact of zebularine treatment on these proteins was also evaluated. While a significant dose dependent decrease in MBD2 levels was observed in MCF-7 cells at the lowest dose, such a decrease was evident only at doses [100 lM in MDA-MB-231 cells (Fig. 4c, d) . Conversely, MBD3 protein expression was very sensitive to zebularine treatment in MDA-MB-231 cells even at the lowest dose, Representative blots from one of three experiments that gave similar results are shown. Blots from all three experiments were quantified densitometrically and mean ± standard deviation is shown for MDA-MB-231 (b) and MCF-7 (c). Asterisk (*) indicates significant difference from control (ANOVA and Tukey's HSD, P \ 0.05) while its expression was decreased only at 200 lM in MCF-7 cells. Effect of zebularine treatment on MeCP2 expression was cell line specific with greater sensitivity in MCF-7 cells than MDA-MB-231 cells (Fig. 4c, d ).
As zebularine decreased expression of multiple proteins associated with transcriptional repression and induced a cell cycle arrest, we speculated that alterations in histone acetylation, a hallmark of transcriptional activity, might be elicited. Indeed, zebularine treatment resulted in dosedependent inhibition of global acetyl H3 and acetyl H4 expression in both the cell lines (Fig. 4e, f) . Zebularine treatment had no effect on histone methylation of dimethylated H3K9, or dimethylated H3K4 in either cell line (data not shown). Zebularine reexpresses ER in ER negative cell lines Given its properties and postulated mechanisms of action, a key question is whether zebularine can alter expression of epigenetically silenced genes. One such gene is estrogen receptor alpha (ESR1 or ER), an important regulator of breast cancer growth and a target for treatment. Because earlier studies have shown that epigenetic silencing associated with hypermethylation of the promoter region is one of the principal mechanisms to silence ER expression in ER-negative breast cancer cells in culture, the ability of zebularine to reexpress ER in MDA-MB-231 cells was evaluated. Zebularine treatment was associated with reexpression of ER mRNA in MDA-MB-231 cells, even at doses as low as 50 lM after 96 h exposure (Fig. 5a ). This appears to have functional consequences as reexpression of the ER target gene, progesterone receptor (PR) was also noted. However, ER-beta gene expression was unaltered at all doses tested (data not shown).
To understand the molecular changes that are associated with the transcriptionally active ER promoter after zebularine treatment of MDA-MB-231 cells, chromatin immunoprecipitation assays were undertaken using primers in the ER promoter region. As shown in Fig. 5b , treatment of MDA-MB-231 cells with zebularine significantly elevated the association of acetylated H4 with the ER promoter while DNMT1, DNMT3a, and DNMT3b were released from the ER promoter. As a positive control, the cells were treated with 2.5 lM of the classic DNMT inhibitor, 5-azaDc for 96 h and similar changes were noted after treatment. These results are consistent with zebularine induction of changes at the ER promoter that favor gene transcription.
Zebularine potentiates the inhibitory effect of other epigenetic therapeutics on cell proliferation and colony formation
This study convincingly provides evidence that as with other cancers, at low doses zebularine is an effective demethylating agent, with minimal toxicity. We next asked whether zebularine can act in concert with other epigenetic modifiers. The combination of low dose zebularine (50 lM) with 1 lM decitabine or 2.5 lM vorinostat led to decreased MDA-MB-231 cell proliferation compared with either drug alone (P \ 0.05) (Fig. 6a) .
To determine whether treatment with zebularine and vorinostat can inhibit clonogenicity, MDA-MB-231 cells were plated as single cells with either 50 lM zebularine or 2.5 lM vorinostat or both. Although clonogenic potential was reduced by zebularine or vorinostat, colonies were absent upon combination treatment (Fig. 6b) .
Discussion
Epigenetic modifications in cancer are reversible events and hence drugs targeting these mechanisms like HDAC and DNMT inhibitors are under evaluation for major cancers including breast cancer. Two DNMT inhibitors, azaC and 5-azaDc, have been shown to be effective in the clinic; their use is limited by toxicity, stability, efficacy, and need for intravenous administration. Hence, there is considerable interest in developing novel DNMT inhibitors that would be more effective and stable and less toxic. Studies in several cancer cell models have supported the use of the DNMT and cytidine deaminase inhibitor, zebularine, as a potent antitumor therapeutic because of its stability [28] , minimal toxicity [18] , and oral bioavailability [15] . In particular it has been found to be very stable with a halflife of 44 h at pH 1.0 and over 500 h at pH 7.0 [29] . For these reasons we assessed the effects of zebularine in human breast cancer cell lines of clinically relevant phenotypes. Our study shows that zebularine induces an S-phase arrest through alteration in expression of cell cycle regulatory proteins and induces changes in protein expression consistent with apoptosis in two human breast cancer cell lines. Alterations of expression of multiple epigenetic regulatory proteins were also observed, generally at 50-100 lM, and expression of a candidate epigenetically regulated gene, ER, was also enhanced at this lower dose. This difference in dose response suggests that the epigenetic regulatory properties of zebularine can be separated from its apoptosis inducing properties, an important finding to support combination studies. As predicted, low doses of zebularine in combination with DNMT or HDAC inhibitors inhibit cell proliferation and colony formation in MDA-MB-231 cells more than either agent alone.
The effect of zebularine on cell proliferation was assayed by MTT. Although minimal effects were seen after 24 h of zebularine exposure, a significant dose and time dependent inhibition of cell proliferation was observed thereafter. The IC50s of zebularine were 150, 99 and 88 lM in MDA-MB-231 and 426, 180 and 149 lM in MCF-7 cells on exposure for 48, 72 and 96 h, respectively. In comparison with MDA-MB-231 cells, MCF-7 cells were less susceptible to zebularine mediated toxicity for uncertain reasons, perhaps related to their lower growth rate. In contrast to other DNMT inhibitors, zebularine is relatively less-toxic to breast cancer cell lines, and these findings are consistent with reports of its effects in other cancer cell lines. For example the IC50s of zebularine in ovarian cancer cells treated for 48 h were 152, 91 and 65 lM in A2780/CP, A2780, and Hey cell lines, respectively, while the IC50 was 120 lM in T24 bladder cancer cells [30] . Treatment of AML-193 myeloid leukemia cells with 250 or 500 lM zebularine led to an approximate 85% inhibition in cell proliferation [16] . Our study confirms that, like in other cell lines, zebularine is minimally toxic to both ER negative and ER positive cell lines at low doses and shorter exposure times.
Because of these growth differences, we further explored the mechanism of action of zebularine in ER-negative and ER-positive breast cancer cell lines. Zebularine induces apoptosis by differential activation of apoptosis signaling cascades in ER positive and ER negative cell lines as previously observed with other agents like sulforaphane [31] . In MDA-MB-231 cells, apoptosis appears to be triggered by both extrinsic and intrinsic pathways through inhibition of antiapoptotic Bcl2 and activation of Bax and caspase-3, leading to cleavage of PARP in a pathway similar to 5-azaDc [32] . The Bax/Bcl2 ratio is increased at all zebularine doses tested, shifting the cells toward apoptosis. These results are consistent with previous reports in This finding suggests errors in chromatin assembly that contribute to genome instability [34] . S-phase arrest can also be triggered by repression of histone synthesis in human cells [35] . It is reported that DNMT1 knock down triggers an intra-S-phase arrest, which is believed to be due to reduction in DNMT1 protein rather than demethylation events [36] . Hence, we believe that the genomic instability induced by DNMT1 down regulation and repression of histone synthesis triggers the activation of S-phase check point proteins like p21 (in MCF-7 cells) and/or down regulates cyclin-D to permit DNA repair before entering G2 phase. The zebularine-mediated decrease in expression of global acetylated histones observed in our studies further supports our hypothesis. In contrast, zebularine did not alter cell cycle in acute myeloid leukemic Kasumi-1 cell lines [37] . However, the highest dose used in that study was 50 lM, while S-phase arrest was evident only at 200 lM in breast cancer cells.
Zebularine is a cytidine deaminase and DNMT inhibitor and its ability to induce epigenetic alterations has already been reported [15, 18] . Here zebularine depleted expression of all three DNMT proteins post-transcriptionally in both breast cancer cell lines at most doses tested. It has been reported that human cancer cells lacking DNMT1 or DNMT3b retain significant global methylation and gene silencing, but those lacking both DNMT1 and DNMT3b had [95% reduction in genomic DNA methylation and virtually absent DNMT activity [38] . Our studies show that zebularine treatment specifically targets DNMT1, and results in partial reduction in DNMT 3a and 3b protein expression, implying that treated cells may still retain substantial methylation. Similar results were seen in T24 bladder cancer cells continuously treated with zebularine for 40 days. In these cells zebularine had no effect on the expression of DNMT1, 3a or 3b mRNA but complete loss of DNMT1 and partial depletion of DNMT 3a and 3b protein were observed [18] .
The ability of zebularine to reactivate expression of epigenetically silenced genes has been evaluated in several model systems. It has been shown that exposure to zebularine reactivates silenced genes including p16 in bladder, colon and prostate cancer cells [15] , E-cadherin in Akata cells [17] and p15INK4B in AML-193 cells [16] . However, p16 expression in zebularine-treated T-24 bladder cancer cells was 10-100-fold lower than that seen with 5-azaDC [13] . That there is some specificity for genes that are reactivated is suggested by the finding that zebularine reactivates silenced E-cadherin without switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells [17] . In addition, the mechanism may not be solely one of demethylation; indeed it was felt that zebularine reactivates silenced genes like P15INK4B in AML-193 cells through regional enrichment of histone acetylation at its promoter [16] .
Because of our previous findings that ER can be epigenetically silenced in some human breast cancer cell lines and HDAC or DNMT inhibitors could reexpress functional ER in ER negative breast cancer cells [24, 25, 39] , we explored if zebularine treatment reactivates ER. Our study demonstrated that treatment of ER negative MDA-MB-231 breast cancer cells with zebularine results in functional ER reactivation as manifested by expression of ER mRNA and its target gene, PR. This was seen with a dose as low as 50 lM, far lower than doses that induced apoptosis. Chromatin immunoprecipitation analysis of the ER promoter in zebularine-treated cells showed characteristics of an active chromatin as manifested by accumulation of acetylated H3 and H4 and release of DNMT1, 3a and 3b from the ER promoter region. Although reexpression of ER with zebularine was not as robust as with 5-azaDc, the low toxicity could enable continuous administration for sustained reexpression of ER.
Some potential limitations for the use of zebularine as a therapeutic do exist. As with other DNMT inhibitors hypothetical concerns exist about specificity; this is a concern about most antineoplastics at present. In addition our studies and others [15] have shown that zebularine is less potent than the two FDA-approved DNMT inhibitors, azaC and 5-azaDc. Doses of 100-500 lM are required for substantial demethylation [17, 19] . It is hypothesized that the reduced inhibitor potency is due to sequestration of the drug by cytidine deaminase, competitive inhibition of zebularine incorporation into DNA by increased cytidine and deoxycytidine that accumulate as a consequence of its cytidine deaminase properties, and preferential incorporation of zebularine into RNA over DNA [30] . For these reasons, the drug is effective only at very high doses, making administration more problematic. However, it has been successfully administered in a long-term study demonstrating its effects as a chemopreventive in the MIN mouse model [40] . Its efficacy combined with a low toxicity profile makes it an attractive agent for combination or sequential therapy with other DNMT or HDAC inhibitors or other biologics.
Cytidine deaminase destabilizes DNMT inhibitors like 5-azaDc, resulting in complete loss of their antineoplastic ability [41] . Hence administration of cytidine deaminase inhibitors like zebularine should theoretically potentiate therapeutic effects of 5-azaDc by slowing its degradation and stabilizing activity. Indeed, the combination of 5-azaDc and zebularine produced greater inhibition in cell proliferation and clonogenicity than either drug alone in leukemic L1210 and HL-60 cell lines [42] . Similarly, treatment of the AML-193 acute myeloid leukemic cell line, which has a densely methylated p15INK4B CpG island, with zebularine followed by the HDAC inhibitor, trichostatin-A, synergistically enhanced p15INK4B expression [16] . Consistent with these results, the combination of 50 lM zebularine and 1 lM 5-azaDc in breast cancer cells significantly inhibited cell proliferation compared with either drug alone. Similarly, zebularine significantly inhibited cell proliferation and colony formation in combination with low doses of vorinostat. Our study forms a basis for novel therapeutic approaches in the treatment of breast cancer through a combination of zebularine and other epigenetic therapeutics.
In conclusion, our data demonstrate that zebularine is an effective demethylating agent, and reactivates a key gene normally silenced in some breast cancer cell lines even at low doses. Zebularine acts through post-transcriptional inhibition of DNMTs, inhibition of methyl CpG binding proteins and alteration of global histone acetylation status. The ability to administer zebularine with other epigenetic therapeutics with at least additive effect has also been established. These results provide a rationale to continue research with zebularine and its derivatives, and explore the development of novel DNMT inhibitors that can be used in combination for breast cancer treatment.
